In vivo administration of nutlin-3a can effectively inhibit the tumor growth of SCID mice, which, for the first time, proves that it is feasible to activate wild-type p53 through a pharmacological inhibitor of p53/MDM2 interaction in vivo (Vassilev et al., 2004). This evidence concerns the gene MDM2 and neoplasm.